Document Details

Document Type : Article In Journal 
Document Title :
Clinical experience with adalimumab in the treatment of ocular Behçet disease
Clinical experience with adalimumab in the treatment of ocular Behçet disease
 
Subject : Ophthalmology 
Document Language : English 
Abstract : PURPOSE: To describe the clinical outcome of refractory ocular Behçet disease with adalimumab therapy. METHOD: Retrospective review of records. RESULTS: Twenty-one eyes of 11 male patients with ocular Behçet disease received adalimumab therapy. Of the 21 eyes, 17 had improvement of visual acuity by more than 3 lines after the average follow-up of 10.8 months. Ten out of 11 patients showed complete resolution of inflammation by 4 weeks. The dosages of corticosteroids and immunosuppressive drugs were reduced in most of the patients and stopped altogether in 3 and 6 patients, respectively. One patient on infliximab showed improvement of inflammation after switching over to adalimumab. No serious side effects were observed in any of the patients. CONCLUSION: Adalimumab appears to be effective in Behçet disease. It has been shown to improve visual acuity and also to have a corticosteroid and immunosuppressive sparing effect. It can induce and maintain sustained remission of the disease 
ISSN : 1744-5078 
Journal Name : Ocular Immunology and Inflammation 
Volume : 18 
Issue Number : 3 
Publishing Year : 1431 AH
2010 AD 
Article Type : Article 
Added Date : Tuesday, August 2, 2011 

Researchers

Researcher Name (Arabic)Researcher Name (English)Researcher TypeDr GradeEmail
أحمد باوزيرBawazeer, Ahmed InvestigatorDoctorate 
لينا رفهRaffa, Lina Researcher  

Files

File NameTypeDescription
 29996.pdf pdf 

Back To Researches Page